Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
The peptide-based vaccine induces a t cell-dependent response
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Subscribe To Our Newsletter & Stay Updated
